Does MD pay a dividend and is it safe?

Pediatrix Medical Group Inc. (MD) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Stock Ratings / Health Care / MD / dividends

BKD (32) SGRY (66) ARDT (69) NHC (72) ⌘ Pro Terminal →

Pediatrix Medical Group Inc. (MD) Dividend Safety Gauge & 10-Year DRIP Compounder

$29.82 +2.19% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $30.01

Pediatrix Medical Group Inc. (MD) earns a Roarable Rating of B+ (Buy) with 77/100 RQD Confidence. High-quality cash engine (steady margins, 34% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

📊 Historical Track Record: Scores of 77/100 (B+) historically ranked in the Top 10% of excess returns over the next 90 days (+7.8% avg 90D alpha vs SPY • 70.3% hit rate) →

ROARABLE B+ • BUY Cap $2.33B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on MD Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is MD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Pediatrix Medical Group Inc. (NYSE: MD) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 77/100 at a spot price of $29.82 (+2.19% 1D, market cap $2.33B). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 17/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 14/20, and SEC Balance-Sheet Forensics 17/20. Across 1016 tracked Health Care issuers, MD ranks #27 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does MD compare to BKD and SGRY in the Health Care sector?

▼

Within the Health Care sector (Hospital/Nursing Management), MD carries a Roarable B+ (77/100 RQD), trailing P/E of 14.3x, gross margin of —, and ROIC of 33.6%. By comparison, BKD (Brookdale Senior Living Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC 0.3%, cap $2.48B) and SGRY (Surgery Partners Inc.) posts a C+ grade (66/100 RQD, P/E N/A, ROIC 9.9%, cap $3.04B). Among the 5-stock peer group, ARDT leads on earnings multiple (12.8x) while MD leads on capital efficiency (33.6% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for MD?

▼

Per MD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000893949), Pediatrix Medical Group Inc. generated $584.7M in revenue (+203.9% YoY), $165.4M in net income, and $271.1M in free cash flow against $2.25B in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $30.01 (+0.63%)🧬 Cannibal Buyback (-2.64% YoY Shares)⚙️ Cash Engine: 16/20 (B+) • 46.4% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 77/100 (B+) historically ranked in the Top 10% of excess returns over the next 90 days (+7.8% avg 90D alpha vs SPY • 70.3% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERBUY • B+

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw A- · Rk C+

Each axis scored 0–20

12M PRICE TARGET CONE+8.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MD)Realized 20D OHLCV Swing Band: ±6.3%

Deterministic 5-Pillar Attribution (77/100 Composite)

🔍 WHY MD SCORES 77/100 (B+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+17/20 pts (22% of score)

20D Institutional Volume Accumulation (±6.3% realized swing band)

▲ #2 Bullish Driver: Insider Conviction & Share Dilution+17/20 pts (22% of score)

SEC Form 4 / 13F Thermometer: 85% Net Buy • Cannibal Buyback (-2.64% YoY Shares)

▼ #1 Drag / Risk Factor: SEC 10-K Forensic Risk13/20 pts (-7 pt drag)

Balance-sheet & 10-K footnote risk deducts 7 pts from forensic ceiling

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B-$26.61+5.5% Next Q

Q2 (-2Q)

Grade B$28.08+2.7% Next Q

Q3 (-1Q)

Grade B+$28.84+3.4% Next Q

Current

Grade B+$29.82+7.8% Hist 90D α

Trajectory: B- (69) → B+ (77)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the MD Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 77/100 (B+) score, MD faces multiple-compression risk if 14.3x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.64% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($27.05) or 200D SMA ($23.94) invalidates the momentum regime and cuts Target Base ($32.37) toward Bear Floor ($24.45).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $MD• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “MD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 77%NO 23%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (6.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $19,307

Est. Year-10 Shareholder Yield: $348/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.7K

Yr 1

$11.4K

Yr 2

$12.2K

Yr 3

$13.0K

Yr 4

$13.9K

Yr 5

$14.8K

Yr 6

$15.8K

Yr 7

$16.9K

Yr 8

$18.1K

Yr 9

$19.3K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Cash-Flow & Quality Compounder Desk

Cash-Fortress Compounders: Auditing Free Cash Flow & Yield Safety in MD & A-Rated Leaders

✓12-month Bull/Base/Bear fair-value walkthrough on MD and its top sector peer
✓Top Roarable A-Rated cash compounders with verified executive & 13F accumulation
✓Includes nightly RQD rating-change & forensic signal email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

MD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +33.07%⚡ TESTING RESISTANCE

2026-11-03O $29.18H $29.82L $29.18C $29.82VOL 1.11M

RES: $30.72SUP: $24.79SMA50: $27.05SMA200: $23.94

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MD Butterfly Map → + Track MD →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

6.2%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on MD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for MD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MD)

Health Care Rank #27 of 1016 ⚔️ BKD vs MD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (MD vs. BKD, SGRY, ARDT, NHC)

Industry: Hospital/Nursing Management (14 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Pediatrix Medical Group Inc. (MD) ranks #27 by composite RQD confidence (77/100, grade B+) and #229 by equity capitalization ($2.33B). Within this direct 5-issuer industry benchmark cohort, ARDT leads on earnings valuation at 12.8x trailing P/E, while MD leads on capital efficiency and profitability with 33.6% ROIC and — gross margin. MD currently leads its immediate peer cohort in composite quantitative strength at 77/100 (B+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
MD ACTIVE Pediatrix Medical Group Inc.	B+	77/100	14.3x	—	33.6%	+2.19%	$2.33B	Benchmark Subject
BKD Brookdale Senior Living Inc.	E	32/100	—	26.2%	0.3%	+1.17%	$2.48B	/bkd-vs-md →
SGRY Surgery Partners Inc.	C+	66/100	—	—	9.9%	0.00%	$3.04B	/sgry-vs-md →
ARDT Ardent Health Inc.	C+	69/100	12.8x	—	10.5%	-2.19%	$1.70B	/ardt-vs-md →
NHC National HealthCare Corporation	B	72/100	27.7x	—	10.1%	-2.84%	$3.23B	/nhc-vs-md →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000893949

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Pediatrix Medical Group Inc. (MD) reported GAAP revenue of $584.7M (+203.9% vs. FY2024 revenue of $192.4M , and +2752.2% cumulative change since FY2023) , GAAP net income of $165.4M, operating cash flow of $271.1M, and free cash flow of $271.1M (+31.2% YoY). On the balance sheet, MD closed FY2025 with $2.25B in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 6/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$584.7M	$165.4M	$271.1M	$271.1M	$2.25B	—
FY2024 (FY)	2024-12-31	$192.4M	-$99.1M	$206.6M	$206.6M	$2.15B	—
FY2023 (FY)	2023-12-31	$20.5M	-$60.4M	$137.3M	$137.3M	—	—

3. MD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does MD compare to BKD and SGRY in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for MD?

Where is MD trading relative to its 50-day, 200-day, and 52-week technical levels?

MD last traded at $29.82 (+2.19% on volume of 1,114,280 shares), positioning the stock +10.24% above its 50-day simple moving average ($27.05) and +24.56% above its 200-day simple moving average ($23.94). Across its 52-week range of $17.23 to $30.55, MD sits at the 94.5% percentile with a 14-day RSI of 67.3 (BULLISH MOMENTUM) and an implied next-earnings move of ±6.3% ($27.94 to $31.70).

Direct Sub-Reports: MD RQD Cockpit MD 12M Forecast MD Earnings & Move MD Dividends & DRIP MD Insiders & 13F MD Whale Options MD Profit Sankey MD News & Why

ROARABLE RATING BRIEF • RQD 77/100 (B+) ✓ STAGE-C NUMBER FIREWALL VERIFIED

MD — Pediatrix Medical Group Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:25:57Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, MD scores 76 out of 100, grading B+ and labeled "Roarable Buy — Very Good Cash & Smart-Money Inflow." The five pillars are:

Fundamental Cash Engine: 16 / 20. Per the RQD rating, this reflects ROIC of 33.6% and an FCF yield of 11.43%. For an investor, these are the strongest quantitative supports in the rating: capital appears to generate high returns, and free cash flow is large relative to the market value.
Whale 13F Flow: 16 / 20. Per the RQD rating, this pillar captures institutional accumulation and options positioning. Positive institutional flow can support the price, but the underlying holder detail is not provided in this dataset.
Insider Conviction: 17 / 20. Per the RQD rating, this is the highest pillar and reflects SEC Form 4 and Congressional PTR cluster flow. Strong insider signaling is a notable upside driver, though the individual transactions are not itemized in the source data.
Macro Regime Fit: 14 / 20. Per the RQD rating, beta is 1.0 with sector sensitivity. For an investor, this means MD is expected to move roughly in line with the broad market, so macro-driven drawdowns are not structurally amplified, but sector-specific shocks remain a factor.
Forensic Balance Sheet: 13 / 20. Per the RQD rating, Altman Z is 2.5, Piotroski F is 6/9, and Debt/Equity is 0.5. This is the lowest pillar, indicating a solid but less pristine balance sheet than the cash and insider pillars suggest.

Valuation tradeoff: per the market data, trailing P/E is 14.3 and forward P/E is 13.3, with EV/EBITDA of 9.6. A prospective investor should weigh the strong cash-flow and insider signals against a valuation that is not stretched on these measures but has already moved meaningfully, as the news wire references a 154% run. The primary upside driver is sustained cash generation and insider conviction; the primary risk is that a balance sheet rated 13/20 offers less cushion if operating conditions weaken.

Business

Pediatrix Medical Group Inc. is a NYSE-listed issuer in the Health Care sector, operating in the Hospital/Nursing Management industry. The profile identifies the business as a hospital and nursing management operator. Revenue is reported as — in each period of the financials, so the revenue-generation mechanics cannot be described from this dataset.

Recent Catalysts & News Wire Analysis

Per the recent news and catalysts feed, six items cover MD:

Green-light catalyst: a TradingView report headlined that Pediatrix Medical Group beats Q3 2026 sales expectations, flagged as a CATALYST with GREEN status.
Yellow-light market wire items: Yahoo Finance and ChartMill coverage describes the stock as undervalued despite a large run and as a value stock trading at a discount with solid profitability. A Yahoo Finance piece covers what management said on its Q3 earnings call. Simply Wall St reports the stock is back in focus. Stock Titan reports revenue rose 1.7% while net income fell to $47 million.
Risk watch item: the Stock Titan headline notes net income declined to $47 million despite revenue growth, which is a margin-quality question to monitor.
Proprietary signals: the Butterfly Supply-Chain Graph reports no proprietary signals and no supply-chain links.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links. Second-order bottlenecks cannot be identified from this dataset. An investor should note that the absence of mapped links is itself a limitation rather than evidence of an absence of dependencies.

Analyst View & Smart Money Ownership

Per the Roarable RQD rating, the insider and whale pillars score 17/20 and 16/20 respectively, but the underlying transactions are not itemized in the holders or analyst sections.

Open Questions

Revenue is reported as — in every period. What is the actual top-line figure, and how do revenue and margins reconcile with the reported operating and net income?
Net income in the Stock Titan headline is cited as $47 million, which differs from the $165.4M FY 2025 figure in the SEC financials. Which period and basis does each figure reflect?
What drove the swing from a FY 2024 operating loss of $-68.7M to a FY 2025 operating income of $208.8M, and is it recurring?
Which institutional and insider transactions make up the 16/20 whale and 17/20 insider pillar scores, and who are the principal holders?
Debt is reported as N/A in every period, so what is the actual debt load behind the stated Debt/Equity of 0.5?

MD Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Pediatrix Medical Group Inc. (MD) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to MD Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 19h ago

Pediatrix Medical Group (MD) Stock Looks Undervalued Despite Its 154% Run

Yahoo Finance report covering Pediatrix Medical Group Inc. (MD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ChartMill • 22h ago

Pediatrix Medical Group (NYSE:MD): A Value Stock Trading at a Discount With Solid Profitability

ChartMill report covering Pediatrix Medical Group Inc. (MD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST TradingView • 1d ago

Pediatrix Medical Group (NYSE:MD) beats Q3 2026 sales expectations

TradingView report covering Pediatrix Medical Group Inc. (MD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

What Pediatrix Medical Group (MD) Said on Its Q3 Earnings Call

Yahoo Finance report covering Pediatrix Medical Group Inc. (MD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

Pediatrix Medical Group (MD) Is Back In Focus, What Are Investors Weighing?

Simply Wall St report covering Pediatrix Medical Group Inc. (MD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Revenue rose 1.7% at Pediatrix, but net income fell to $47 million.

Stock Titan report covering Pediatrix Medical Group Inc. (MD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

Pediatrix Medical Group (MD) reports earnings tomorrow: what to expect

TradingView report covering Pediatrix Medical Group Inc. (MD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

Pediatrix Medical Group (MD) Stock Climbs As Q3 Earnings Back Resilience

Simply Wall St report covering Pediatrix Medical Group Inc. (MD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

MD Bull vs. Bear Conversation Board — What's Your Call at $29.82?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON MD 🐻 33% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐂 BULLISH 🎯 Target: $34.43 (+18.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is MD (B+ • RQD 76/100) a Buy at $29.18?

Welcome to the MD (Pediatrix Medical Group Inc.) Roar Pit. Current RQD Composite is 76/100 (Roarable Buy — Very Good Cash & Smart-Money Inflow) in Hospital/Nursing Management. Bulls point to capital efficiency (33.6% ROIC), while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SK SkepticalCFA Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $22.47 (-23.0%)

Spot @ $29.18

Pump the brakes on MD — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on MD, but look at what you are paying: 14.3x trailing P/E with tightening sector spreads. Unless Pediatrix Medical Group Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

CA CashFlowKing Verified K Arena Trader 🐂 BULLISH 🎯 Target: $36.77 (+26.0%)

Spot @ $29.18

MD cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on MD, the market is fixating on short-term headline noise in Hospital/Nursing Management and ignoring the balance sheet and cash flow trajectory. At $29.18 (52-wk range $16.90 - $30.55), any beat on forward guidance forces shorts and underweight funds to chase.